Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma
Abstract
INTRODUCTION: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab. CASE PRESENTATION: We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence. CONCLUSION: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies.
Fields of Study & Subjects
Methemoglobinemia and Tumor Lysis Syndrome
Blood disorders and treatments
Hematological disorders and diagnostics
Publication details
- Journal / source
- Revista de la Facultad de Ciencias Médicas de Córdoba
- Publisher
- Universidad Nacional de Córdoba
- Volume
- 83
- Issue
- 1
- Pages
- e49234–e49234
- Publication date
- 30 March 2026
- Language
- EN